The previous studies of CTECs in breast cancer mostly focused on monitoring treatment efficacy [31, 32], especially antivascular endothelial growth factor-A (anti-VEGF-A) antibody bevacizumab [33–35]. This evidence concerns the gene VEGFA and breast carcinoma.